USP, GMP, and Drug Master Files: Manufacturing Deep Dive

Why Manufacturing Standards Matter

In the previous article, we covered the tests used to evaluate peptide quality. But testing alone is not enough — testing catches problems after the fact. Manufacturing standards are the systems and processes designed to prevent problems from occurring in the first place. The difference between a high-quality compounding pharmacy and a questionable one often comes down not to the final product test results, but to the rigor of the manufacturing environment that produced it.

Good Manufacturing Practice (GMP)

Good Manufacturing Practice (GMP), or more specifically Current Good Manufacturing Practice (cGMP), is a set of regulations enforced by the FDA that govern the production, processing, and packaging of pharmaceutical products. The "current" in cGMP means that manufacturers must stay up to date with the latest standards — compliance is not a one-time achievement but an ongoing obligation.

GMP regulations cover virtually every aspect of pharmaceutical manufacturing:

• Facility design and maintenance. Manufacturing areas must be designed to prevent contamination — with controlled airflow, appropriate HVAC systems, cleanroom classifications, and separation between different production areas.
• Equipment qualification. All equipment must be validated to perform consistently and accurately. This includes regular calibration, preventive maintenance, and documentation of all equipment activities.
• Personnel training. All staff involved in manufacturing must receive documented training appropriate to their role. This includes aseptic technique for anyone involved in sterile compounding.
• Raw material controls. All starting materials must be tested and verified before use. This includes identity testing (confirming the raw material is what it claims to be), purity testing, and documentation of the source and chain of custody.
• Process validation. Manufacturing processes must be validated — meaning demonstrated, through documented evidence, to consistently produce a product meeting its predetermined quality attributes.
• Documentation and record-keeping. Every step of the manufacturing process must be documented in real time. "If it is not documented, it did not happen" is the foundational GMP principle.
• Quality control and quality assurance. An independent quality unit must review and approve all materials, processes, and finished products before release.

For 503B outsourcing facilities, cGMP compliance is a federal requirement. The FDA conducts inspections to verify compliance, and facilities found in violation can receive warning letters, consent decrees, or be shut down. For 503A compounding pharmacies, cGMP requirements are generally less stringent, though USP standards (discussed below) impose their own quality requirements.

USP Standards for Compounding

The United States Pharmacopeia (USP) is an independent, nonprofit organization that sets quality standards for medicines sold in the United States. For compounding pharmacies, three USP chapters are particularly relevant:

• USP <795> governs non-sterile compounding — preparation of oral medications, topical creams, and other products that do not require sterility. This chapter establishes standards for ingredient quality, beyond-use dating, and compounding procedures.
• USP <797> governs sterile compounding — the preparation of injectable products, ophthalmic solutions, and other sterile medications. This is the chapter most relevant to peptide compounding. USP <797> specifies requirements for cleanroom environments, personnel training, garbing procedures, environmental monitoring, and beyond-use dating for sterile preparations.
• USP <800> governs the handling of hazardous drugs, which may apply to certain compounds handled in pharmacies that also prepare peptides.

USP <797> was significantly revised in 2023, with stricter requirements for environmental monitoring, personnel competency assessment, and beyond-use dating. These revisions raised the bar for sterile compounding across the industry.

Compliance with USP standards is enforced primarily by state boards of pharmacy, which conduct inspections of compounding operations within their jurisdictions. The rigor of these inspections varies by state — some states have robust inspection programs, while others are less thorough.

Drug Master Files

A Drug Master File (DMF) is a submission to the FDA that provides detailed information about the manufacturing processes, facilities, and quality controls used to produce a pharmaceutical ingredient. DMFs are typically filed by Active Pharmaceutical Ingredient (API) manufacturers — the companies that produce the raw peptide powder that compounding pharmacies then use.

When a compounding pharmacy sources its peptide raw material from an API manufacturer with an active DMF on file with the FDA, it means the FDA has access to detailed information about how that raw material is produced. This provides an additional layer of transparency and accountability in the supply chain.

Not all API manufacturers file DMFs, and having a DMF does not mean the FDA has approved the material — it simply means the information is available for FDA review. However, sourcing from DMF-supported suppliers is generally considered a quality indicator.

Monographs: Official Quality Specifications

A monograph is an official, published set of quality specifications for a specific substance. USP monographs define the tests, procedures, and acceptance criteria that a substance must meet to be considered pharmacopoeia-grade. When a USP monograph exists for a peptide, any compounding pharmacy using that peptide should be testing against those specifications.

For many compounded peptides, no USP monograph exists — the peptide has not been through the process of establishing official quality standards. In these cases, the compounding pharmacy must develop its own quality specifications based on available scientific literature and analytical capabilities. This is not inherently problematic, but it means there is less standardization across pharmacies.

How to Evaluate a Compounding Pharmacy's Standards

When assessing a compounding pharmacy as a source for peptides, consider asking:

• Is the pharmacy licensed and in good standing with its state board of pharmacy?
• Is it PCAB/ACHC accredited? (Voluntary but indicates third-party quality assessment)
• If it claims 503B status, is it registered on the FDA's public list?
• Where does it source its raw materials? Are they from DMF-supported manufacturers?
• Does it test finished products for identity, purity, potency, sterility, and endotoxins?
• Can it provide batch-specific COAs from accredited third-party laboratories?
• Does it comply with USP <797> for sterile compounding?
• Has it received any FDA warning letters or state board disciplinary actions? (Both are publicly searchable)

No single question is definitive, but the pattern of answers reveals whether a pharmacy operates at a high standard or cuts corners.

This article is for informational purposes only and does not constitute medical or legal advice.

Next, we examine the regulatory policy landscape in depth — the laws, agencies, and policy debates that shape peptide access today and into the future.